Developing a dedicated CT device to be used in cardiology departments, for fast and easy diagnosis of cardiovascular diseases.

Name: Arineta LTD

Founders: Dr. Ehud Dafni and MR.

CEO: Dr. Ehud Dafni

Sector: Medical Devices
Sub-Sector: Imaging
Medical Field: Cardiovascular
Est.: 2006
Stage: Seed

Vision: To make heart CT examination part of the regular treatment that every heart patient receives, thereby leading to earlier diagnosis of heart diseases, better treatment and decline in mortality rate.

Website: http://www.arineta.com/

Cardiovascular disease is the leading cause of death and disability in Israel and other developed countries. In the US alone, more than 1,200,000 people suffer heart attacks each year. Most of them get to a hospital for treatment, and there begins the usual chaos: they are sent from the ER to cardiology, where the doctor promptly sends them onwards to catheterization – an invasive and costly procedure. Typically, 30% – 40% of catheterization procedures turn out to be diagnostic only, without need for therapeutic intervention.

Big waste of money? Perhaps, but it’s not like there are better choices for the cardiologists. Ideally, they would need an imaging device dedicated for heart imaging. A CT (computed tomography) can do that, but currently it is operated only by radiologists, and not many MDs would send a heart patient to stand in line for another department of the hospital. Some will probably never return, if only because of the length of the line and the limited life expectancy of most patients.

Dr Ehud Dafni is dead-fixed on changing the current procedures for treatment of heart patients.  To that end he founded Arineta Ltd in late 2006, together with Mr. Yosi Morik, an experienced businessman and entrepreneur. Arineta’s crew of researchers and engineers is currently developing a new class of cost effective, dedicated cardiac CT scanners, which provide superior imaging performance, and low X-ray dose. According to Dr Dafni, These devices would be relatively cheap and easy to operate, so that each cardiology department could have one of its own. The result: better diagnosis and treatment options for each and every patient, without having to set foot outside the department’s boundaries.

Until now, the money for the development – more than two million dollar – arrived from private investors, who seem confident that this investment will bear fruit. However, as Arineta will be going into the next phase, higher budgets will be needed. Biomed Israel will keep an eye on the young company through its maturation process, and we’ll keep our fingers crossed for them – and for a better heart treatment for all of us!

Share on Facebook

Popularity: 43% [?]